LRFN5 as A Drug Target Or Biomarker for Neurological Disorders

Target Name: LRFN5

NCBI ID: G145581

LRFN5

Other Name(s): FIGLER8 | Leucine-rich repeat and fibronectin type-III domain-containing protein 5 | SALM5 | C14orf146 | Leucine rich repeat and fibronectin type III domain containing 5, transcript variant 1 | Fibronectin type III, immunoglobulin and leucine rich repeat domains 8 | LRFN5 variant 1 | LRFN5_HUMAN | fibronectin type III, immunoglobulin and leucine rich repeat domains 8 | Leucine-rich repeat and fibronectin type-III domain-containing protein 5 (isoform 1) | leucine rich repeat and fibronectin type III domain containing 5

LRFN5 as A Drug Target Or Biomarker for Neurological Disorders

LRFN5 (Long Short-Term Memory-associated protein 5) is a protein that is expressed in various tissues and cells throughout the body. It is a member of the superfamily of transmembrane protein and is characterized by a unique N-terminal region that is rich in conserved amino acid sequence. LRFN5 is highly expressed in the brain and is involved in various cellular processes, including memory and learning.

Recent studies have suggested that LRFN5 may be a drug target or biomarker for various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression. This is because LRFN5 has been shown to play a role in the development and progression of these disorders, as well as in their treatment.

One of the key mechanisms by which LRFN5 is thought to contribute to the development of these disorders is its role in the formation of neurodegradative tangles, which are thought to be a hallmark of Alzheimer's disease. tangles are composed of a variety of protein aggregates, including LRFN5, that can accumulate in the brain and contribute to its progressive neurodegeneration.

Additionally, LRFN5 has been shown to be involved in the regulation of neurotransmitter release, which is critical for the function of many nervous systems. LRFN5 has been shown to interact with dopamine, a neurotransmitter that is involved in mood, motivation, and movement. This interaction suggests that LRFN5 may play a role in the treatment of depression and other psychiatric disorders associated with imbalances in neurotransmitter release.

Another potential mechanism by which LRFN5 may contribute to the development of these disorders is its role in the regulation of cellular signaling pathways. LRFN5 has been shown to interact with a variety of signaling pathways, including TGF-beta, which is involved in cell growth and differentiation. This interaction suggests that LRFN5 may play a role in the regulation of cellular processes that are important for the development and progression of these disorders.

In conclusion, LRFN5 is a protein that is expressed in various tissues and cells throughout the body and is involved in various cellular processes that are important for the development and progression of neurological and psychiatric disorders. Its role in the formation of neurodegradative tangles, regulation of neurotransmitter release, and regulation of cellular signaling pathways suggests that LRFN5 may be a drug target or biomarker for these disorders. Further research is needed to fully understand the role of LRFN5 in the development and progression of these disorders.

Protein Name: Leucine Rich Repeat And Fibronectin Type III Domain Containing 5

Functions: Cell adhesion molecule that mediates homophilic cell-cell adhesion in a Ca(2+)-independent manner. Promotes neurite outgrowth in hippocampal neurons

The "LRFN5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRFN5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets